(July 27, 2022, 8:22 AM EDT) -- CHICAGO — Generic drugmaker Impax Laboratories LLC has agreed to pay $145 million to settle a multidistrict litigation antitrust class action by direct purchasers alleging that the company violated the Sherman Act when it entered into an anticompetitive reverse payment settlement agreement with Endo Health Solutions Inc. to delay generic competition for the opioid Opana ER, resulting in buyers being overcharged for the drug, according to a motion filed July 19 in Illinois federal court....